Scott Dreyer
Corporate Officer/Principal bei COLLEGIUM PHARMACEUTICAL, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Scott Dreyer is currently the Chief Commercial Officer & Executive VP at Collegium Pharmaceutical, Inc. He previously worked as the Vice President-US Hospital & Oncology Sales at Merck & Co., Inc. from 1994 to 2013.
From 2014 to 2016, he served as the Chief Marketing Officer at Biogen, Inc. He then worked as the Senior VP-Marketing & Commercial Operations at The Medicines Co. from 2016 to 2017.
Mr. Dreyer completed his undergraduate degree at the University of Messiah in 1994.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.03.2024 | 33 016 ( 0,10% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Scott Dreyer
| Unternehmen | Position | Beginn |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Corporate Officer/Principal | 10.07.2018 |
Ehemalige bekannte Positionen von Scott Dreyer
| Unternehmen | Position | Ende |
|---|---|---|
| THE MEDICINES COMPANY | Sales & Marketing | 01.12.2017 |
| BIOGEN INC. | Sales & Marketing | 01.09.2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2013 |
Ausbildung von Scott Dreyer
| University of Messiah | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
